Posting of Notice of AGM

EDX Medical Group PLC

04 September 2023

 

Posting of Notice of AGM

EDX Medical Group PLC · EDX

4 September 2023

EDX Medical Group PLC ("EDX Medical" or the "Company"), which develops innovative digital diagnostic products and services supporting personalised treatment solutions for cancer, heart disease, neurology and infectious diseases, announces that its annual general meeting ("AGM") will be held in the Roosevelt Room at Brown's Hotel, 33 Albemarle St, London, W1S 4BP at 2:00 p.m. on Wednesday, 27 September 2023.

The Notice of AGM and Form of Proxy will be posted today, 4 September 2023, to eligible shareholders. Electronic copies will be shortly available on the Company's website at: https://edxmedical.co.uk/documents/.

Due to the acquisition of a subsidiary company during the reporting period, EDX Medical's annual report and accounts will be published prior to the AGM and resolutions to receive the annual report and accounts, and to re-appoint the auditors, will be presented at a later general meeting in October 2023.

Contacts:

EDX Medical PLC
Dr Mike Hudson (Chief Executive Officer)	[phone] [e-mail]
Oberon Capital
Nick Lovering (Corporate Adviser) Adam Pollock (Corporate Broking) Mike Seabrook (Corporate Broking)	[phone]
Media House International
Ramsay Smith (Executive Director) Gary McQueen (Associate Director)	[phone] [e-mail] + 44 (0)7834 694609 [e-mail]

Notes for Editors:

About EDX Medical Group

www.edxmedical.co.uk

EDX Medical Group PLC develops innovative digital diagnostic products and services, enabling cost effective and timely delivery of personalised treatment for cancer, heart disease, neurology and infectious diseases. The company is listed on the Access Segment of the AQSE Growth Market (TIDM: EDX).

EDX Medical was founded by Professor Sir Christopher Evans, OBE, a medical and life sciences entrepreneur with more than 30 years of experience, together with CEO, Dr Mike Hudson.

By translating clinical insights into pragmatic solutions combining advanced biological and digital technologies, EDX Medical seeks to cost-effectively improve the detection and characterisation of disease in order to personalise treatment in a timely fashion. Early disease detection and biologically-based personal treatment optimisation is considered to be the most impactful way of reducing deaths and lowering the cost of healthcare globally.

EDX Medical operates a molecular biology and diagnostics laboratory in Cambridge, UK, and the 100%-owned subsidiary "Torax Biosciences Ltd" (www.toraxbiosciences.co.uk) with a satellite operation in Ireland. EDX Medical provides testing and genomic sequencing services, undertakes quality assurance, conducts research & development (R&D) and has established expertise in the design, development, validation and sourcing of diagnostic testing solutions to ISO 13485. Key laboratory tests performed by the Company have been accredited to ISO 15189 by the United Kingdom Accreditation Service (UKAS).

 

END